Akebia Therapeutics (AKBA) Issues Quarterly Earnings Results, Beats Estimates By $0.61 EPS

Akebia Therapeutics (NASDAQ:AKBA) released its quarterly earnings data on Monday. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.61, Bloomberg Earnings reports. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%.

Akebia Therapeutics (NASDAQ:AKBA) opened at $13.52 on Tuesday. The firm has a market capitalization of $639.08, a price-to-earnings ratio of -4.28 and a beta of 0.80. Akebia Therapeutics has a twelve month low of $8.69 and a twelve month high of $20.25.

Several research firms recently issued reports on AKBA. ValuEngine cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Monday, November 13th. BTIG Research began coverage on Akebia Therapeutics in a report on Thursday, December 7th. They set a “buy” rating and a $30.00 price target on the stock. Piper Jaffray Companies began coverage on Akebia Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Mizuho reissued a “buy” rating and set a $24.00 price target on shares of Akebia Therapeutics in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $22.20.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/03/13/akebia-therapeutics-akba-issues-quarterly-earnings-results-beats-estimates-by-0-61-eps.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply